

Adaptation in CRISPR-Cas systems

Samuel H. Sternberg^{1†}, Hagen Richter^{2†}, Emmanuelle Charpentier^{2,3,4,5*} and Udi Qimron^{1*}

¹ *Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel*

² *Helmholtz Centre for Infection Research, Department of Regulation in Infection Biology, Braunschweig 38124, Germany*

³ *Max Planck Institute for Infection Biology, Department of Regulation in Infection Biology, Berlin 10117, Germany*

⁴ *The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå Centre for Microbial Research (UCMR), Department of Molecular Biology, Umeå University, Umeå 90187, Sweden*

⁵ *Hannover Medical School, Hannover 30625, Germany*

† Equal contribution

*To whom correspondence should be addressed. Emails: charpentier@mpiib-berlin.mpg.de and ehudq@post.tau.ac.il

1 **Abstract**

2 Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-
3 associated proteins (Cas) constitute an adaptive immune system in prokaryotes. The system
4 preserves memories of prior infections by integrating short segments of foreign DNA,
5 termed spacers, into the CRISPR array in a process termed adaptation. During the last three
6 years, significant progress has been made on the genetic requirements and molecular
7 mechanisms of adaptation. Here we review these recent advances, with a focus on the
8 experimental approaches that have been developed, the insights they generated, and a
9 proposed mechanism for self versus non-self discrimination during the process of spacer
10 selection. We further describe the regulation of adaptation and the protein players involved
11 in this fascinating process that allows bacteria and archaea to harbor adaptive immunity.

12 **Introduction**

13 Most archaea (~90%) and many bacteria (~50%) encode CRISPR-Cas (clustered regularly
14 interspaced short palindromic repeats – CRISPR associated) systems that are adaptive
15 immune systems against mobile genetic elements (MGEs) (Makarova et al., 2015). The
16 mechanisms involved in immunity rely on small CRISPR RNAs (crRNAs) that guide Cas
17 protein(s) to cleave complementary foreign nucleic acids in a sequence-specific manner
18 (Barrangou et al., 2007; Brouns et al., 2008; Garneau et al., 2010; Hale et al., 2009;
19 Marraffini and Sontheimer, 2008). The hallmark of CRISPR-Cas systems is the CRISPR
20 array that consists of short repeated sequences (repeats) interspersed by unique sequence
21 elements (spacers), which frequently derive from mobile genetic elements such as plasmids
22 and viruses (bacteriophages/phages) (Pourcel et al., 2005; Bolotin et al., 2005; Mojica et
23 al., 2005). The array is preceded by an AT-rich leader containing a promoter. Transcription
24 of the CRISPR array generates precursor RNA molecules that are further processed to
25 generate the mature crRNAs. In this setting, spacer sequences provide the sequence
26 specificity for interference with invading nucleic acids.

27 The *cas* genes, located proximal to the CRISPR array, encode the Cas proteins that play
28 roles in the different stages of immunity. According to a recently updated classification,
29 CRISPR-Cas systems can be grouped into class I and class II systems, where interference
30 is carried out by multiple proteins or a single effector protein, respectively. Based on the
31 presence of signature proteins, these classes are further subdivided into Types I, III, IV,
32 and II, V, VI systems, respectively (Makarova et al., 2015). Following invasion of an MGE,
33 the CRISPR-Cas system acts in three steps: i) adaptation (or acquisition), in which a new
34 spacer derived from an invading sequence is inserted into the CRISPR array, ii) crRNA
35 biogenesis, in which the CRISPR array is transcribed and the resulting precursor crRNA is
36 processed into mature crRNAs, and iii) interference, in which the foreign nucleic acid is
37 targeted and degraded by a Cas-crRNA ribonucleoprotein complex (Marraffini, 2015).

38 Barrangou and colleagues (Barrangou et al., 2007) were the first to demonstrate the
39 adaptive feature of CRISPR-Cas immunity, confirming the earlier hypotheses that the
40 CRISPR-Cas system conveys immunity against mobile genetic elements (Makarova et al.,

41 2006; Mojica et al., 2005; Pourcel et al., 2005). Challenging the bacterium *Streptococcus*
42 *thermophilus* with phage resulted in the acquisition of phage-originating spacers into the
43 CRISPR array, which provided resistance to matching phages upon further infection. The
44 identification of spacer uptake upon phage challenge proved to be an efficient measure to
45 analyze population dynamics, as several studies of the Banfield lab could demonstrate.
46 Long-term co-culture experiments combined with metagenomic approaches showed that
47 spacer uptake is a key factor that drives phage evolution (Paez-Espino et al., 2015; Sun et
48 al., 2015).

49 Two modes of adaptation have been reported for Type I systems: i) naïve and ii) primed
50 (Datsenko et al., 2012; Swarts et al., 2012; Yosef et al., 2012). During naïve adaptation,
51 the organism obtains a spacer from a foreign DNA source. In contrast, primed acquisition
52 relies on a pre-existing (priming) spacer that enables a biased and enhanced uptake of new
53 spacers. Both modes are based on the action of two key proteins, Cas1 and Cas2. Naïve
54 adaptation requires only Cas1 and Cas2 (Yosef et al., 2012), whereas primed adaptation
55 additionally requires the Type I interference complex Cascade (CRISPR associated
56 complex for antiviral defense) and the Cas3 nuclease (Datsenko et al., 2012; Fineran et al.,
57 2014; Swarts et al., 2012). Other CRISPR-Cas types encode additional proteins that appear
58 to be involved in spacer acquisition. In the Type I-A system of *Thermoproteus tenax*, a
59 larger complex formed by Cas1, Cas2, Cas4 and Csa1 was reported *in vitro* (Plagens et al.,
60 2012). *In vivo* acquisition in Type I-B system of *Haloarcula hispanica* demonstrated direct
61 involvement of Cas4 in adaptation (Li et al., 2014b). In addition to Cas1 and Cas2, the two
62 proteins Csn2 and Cas9 play essential roles for Type II-A acquisition of *S. thermophilus*
63 and *Streptococcus pyogenes* (Heler et al., 2015; Wei et al., 2015b).

64 For identifying a suitable protospacer for acquisition, Type I and Type II systems employ
65 short 3–7 base-pair (bp) protospacer adjacent motifs (PAM) (Deveau et al., 2008; Garneau
66 et al., 2010; Horvath et al., 2008; Jinek et al., 2012; Mojica et al., 2009; Saprunauskas et
67 al., 2011). During naïve adaptation in Type II systems Cas9 recognizes the PAM (Heler et
68 al., 2015; Wei et al., 2015b), whereas in Type I-E systems, Cas1 and Cas2 are sufficient
69 for PAM recognition (Wang et al., 2015; Yosef et al., 2012). Following protospacer
70 selection and processing, the acquisition machinery performs site-specific integration of

71 the new spacer into the CRISPR array at the leader end, concurrent with duplication of the
72 first repeat. Both the leader sequence and the first repeat were shown to be essential, and
73 studies of the *Escherichia coli* Type I-E and the *S. thermophilus* Type II-A systems suggest
74 that the leader-repeat boundary serves as an anchor for spacer integration (Wei et al.,
75 2015a; Yosef et al., 2012).

76 In this review, we summarize recent advances in our understanding of adaptation in
77 CRISPR-Cas immune systems. We describe the experimental approaches that have been
78 developed to monitor spacer acquisition, and discuss features of naïve and primed
79 adaptation, self- vs. non-self discrimination and regulatory components for the adaptation
80 process. Finally, we highlight some future directions and remaining key questions. Table
81 1 summarizes the model organisms discussed in the review.

82 **Methods for studying adaptation in CRISPR-Cas systems**

83 Five years after the first demonstration of natural spacer acquisition in *S. thermophilus*,
84 five assays were independently developed for the Type I-E CRISPR-Cas system,
85 establishing a basic framework for later studies, including a subsequent *in vitro* adaptation
86 assay as described below.

87 To determine the DNA elements and proteins required for adaptation, an assay was
88 developed in which plasmid-encoded Cas1 and Cas2 were co-expressed for 1 to 3 days in
89 an *E. coli* containing a CRISPR array but lacking *cas* genes (Yosef et al., 2012). PCR
90 amplification of a short segment between the leader sequence and the existing spacers on
91 the CRISPR array was conducted using genomic DNA. Gel electrophoresis analysis
92 revealed two major bands: one band of a CRISPR array amplified from DNA of the
93 parental bacteria (no acquisition) and a second band expanded by 61 bp in size, amplified
94 from DNA of bacteria that did acquire a new spacer (Fig. 1A). Sequences of individual
95 acquired spacers were subsequently analyzed. Reliable detection of adaptation could be
96 achieved if 1% or more of the bacteria acquired new spacers. In following studies, gel
97 extraction of the expanded band and high-throughput DNA sequencing allowed the
98 detection of less than 0.01% bacteria that acquired spacers. This enabled the detection of
99 spacer acquisition at more physiological conditions, such as low Cas1 and Cas2 expression

100 (Levy et al., 2015; Savitskaya et al., 2013; Yosef et al., 2013). A modified PCR protocol
101 using donor protospacer-specific primers results in DNA amplification only when the
102 spacer of the corresponding donor protospacer is inserted into the CRISPR array, enabling
103 greater sensitivity and direct comparison of adaptation efficiencies between different
104 potential protospacer sequences (Fig. 1B)(Yosef et al., 2013).

105 Another assay for monitoring spacer acquisition relies on positive selection of bacteria with
106 expanded CRISPR arrays (Diez-Villasenor et al., 2013). By placing the CRISPR array
107 upstream of an out-of-frame antibiotic-resistance gene, spacer acquisition and repeat
108 duplication with subsequent restoration of the open reading frame can be monitored via
109 recovery of an antibiotic resistance phenotype (Fig. 1C). Since rare acquisition events were
110 positively selected, spacer acquisition was detected even under conditions of low Cas1 and
111 Cas2 (Diez-Villasenor et al., 2013).

112 A significant advancement for studying adaptation has been the establishment of an *in vitro*
113 system that monitors spacer acquisition intermediates in the *E. coli* Type I-E system
114 (Nunez et al., 2015b). In reactions with purified *E. coli* Cas1 and Cas2, supercoiled plasmid
115 DNA containing a CRISPR array and dsDNA serving as a spacer donor, acquisition
116 products were observed by agarose gel electrophoresis and subjected to high-throughput
117 DNA sequencing (Fig. 1D). Importantly, the system enabled testing different spacer
118 donors, which had not been possible with the *in vivo* studies (Nunez et al., 2015b).
119 Nevertheless, the assay showed only intermediates of adaptation, i.e. half-site integration
120 rather than fully integrated spacers.

121 The above assays were used to detect naïve adaptation. An assay monitoring *E. coli* Type
122 I-E CRISPR-dependent plasmid curing over time revealed the involvement of interference
123 proteins in primed adaptation (Swarts et al., 2012). Bacteria expressing the entire set of
124 Cas proteins were propagated for 7-14 days. Plating the bacteria with or without antibiotic
125 was then used to monitor plasmid curing. Bacteria cured of the plasmid were analyzed for
126 spacer acquisition by sequencing of the amplified CRISPR array (Fig. 1E). A modified
127 assay monitored spacer acquisition under similar conditions but with bacterial strains that
128 already contained a plasmid-targeting spacer, thereby facilitating primed adaptation

129 (Savitskaya et al., 2013; Shmakov et al., 2014). This assay enabled high-throughput
130 monitoring of spacer acquisition after just a single overnight growth. Primed spacer
131 acquisition was also observed upon infection by M13 phage when a phage-targeting spacer
132 already existed in the CRISPR array (Datsenko et al., 2012) (Fig. 1F). Taken together, the
133 above-described assays are the major methods to monitor and characterize adaptation.

134 **Adaptation in Type I CRISPR-Cas systems**

135 *Naïve adaptation*

136 Using the PCR-based assay described above (Yosef et al., 2012), it was shown that in the
137 *E. coli* Type I-E system, Cas1 and Cas2 are both necessary for spacer acquisition. The
138 DNase activity of Cas1 is required since a Cas1^{D221A} nuclease deficient mutant (Babu et
139 al., 2011), did not support spacer acquisition *in vivo*. The study determined that a single
140 repeat is both necessary and sufficient. By testing two variants of functional repeats
141 followed by sequencing of the newly duplicated repeat, it was shown that the inserted
142 repeat is identical to the leader-proximal repeat, indicating that this repeat is copied during
143 spacer adaptation (Yosef et al., 2012). These experiments further demonstrated that the
144 minimal required length of the leader is 40 to 60 bp upstream of the first repeat of the array,
145 which was later refined to be 40 to 43 bp (Diez-Villasenor et al., 2013).

146 Protospacers with a flanking 5'-AAG-3' PAM sequence were selected as donors with
147 ~35% frequency indicating that these spacers are overrepresented compared to the PAM
148 frequency (~1.6%). The absence of selection for functional spacers during interference
149 indicates that the acquisition machinery has an intrinsic ability to recognize the correct
150 PAM. Lower expression of Cas1 and Cas2 resulted in more spacers having AAG PAMs
151 (Qimron and colleagues, unpublished). Cascade and Cas3 further increased this stringency
152 due to an unknown mechanism (see below). The GC content of different protospacers did
153 not affect acquisition efficiency (Swarts et al., 2012). However, an AA motif at the end of
154 the spacer sequence did increase adaptation efficiency, as determined by both low and
155 high-throughput analyses (Fineran et al., 2014; Yosef et al., 2013).

156 Mechanistically, the above mentioned *in vitro* assay using purified Cas1 and Cas2 proteins
157 revealed that dsDNA rather than ssDNA is the preferred substrate for adaptation (Nunez et

158 al., 2015b). The 3'-OH ends are essential features to make a nucleophilic attack on one
159 strand of the repeat. Cas1 and Cas2 integrate a spacer with the correct PAM orientation by
160 preferentially using the 3'-OH C nucleotide that is complementary to the G of the AAG
161 PAM. These results, along with intermediate adaptation products identified *in vivo* (Arslan
162 et al., 2014), suggest a model for naïve adaptation in the *E. coli* Type I-E system (Fig. 2).
163 Because only reaction intermediates were monitored, some *in vivo* adaptation features were
164 not observed using the *in vitro* assay (Nunez et al., 2015b). Whereas the integration of new
165 spacers occurs adjacent to the leader-proximal repeat *in vivo*, spacer insertion was also
166 observed at other repeats and even outside the CRISPR array *in vitro*. Furthermore, the
167 length of new spacers varied substantially *in vitro*, while a strictly defined length of spacers
168 is observed in natural arrays. The *in vitro* system, however, reflects only the final stages of
169 spacer integration, i.e. the donor DNA is supplied in a ready-to-integrate form, and prior
170 processing steps may specify spacer length and PAM preference (Yosef and Qimron,
171 2015). Selection and processing of the spacer donor from foreign DNA has yet to be
172 demonstrated and it is not yet known how other proteins might facilitate hand-off of spacer
173 donors to Cas1 and Cas2.

174 Interestingly, naïve adaptation was not observed in two studies on Type I-B and I-F
175 systems. Here, adaptation strictly required the priming process (Li et al., 2014b; Richter et
176 al., 2014). Given that self-adaptation may pose a serious threat in constitutively active
177 systems, a prerequisite for priming may be reasonable. In addition, it is possible that naïve
178 adaptation occurs in these systems under conditions that have not yet been determined.

179 *Primed adaptation*

180 Primed adaptation is characterized by an increased efficiency of spacer acquisition in the
181 presence of Cas1, Cas2, Cascade, Cas3, and a 'priming' spacer targeting an existing
182 protospacer. In the absence of any of these components, primed adaptation does not occur
183 (Datsenko et al., 2012). In Type I-E system priming enhances acquisition 10 to 20 fold
184 over naïve adaptation (Datsenko et al., 2012; Savitskaya et al., 2013). The overall
185 efficiency of priming is significantly increased when the priming spacer has mutations in
186 the seed sequence or if the protospacer has a non-cognate PAM (Datsenko et al., 2012).

187 This suggests that priming likely evolved as a mechanism to minimize infection by phage
188 escape mutants that would otherwise evade the interference machinery (Datsenko et al.,
189 2012).

190 Primed adaptation in Type I-E is biased to the strand orientation matching that of the
191 protospacer targeted by the priming spacer. In early experiments, it was shown that
192 multiple rounds of adaptation exclusively resulted in spacers acquired in the same
193 orientation of the first spacer (Swarts et al., 2012). This observation was later validated in
194 a controlled experiment in which primed adaptation was monitored from two plasmids
195 harboring protospacers in either forward or reverse orientation. Increased spacer
196 acquisition in one strand of the plasmid corroborated the orientation of the protospacer,
197 indicating that acquisition is facilitated from a primed strand (Datsenko et al., 2012). This
198 feature is not conserved in all Type I systems, as both Type I-B and Type I-F systems in
199 contrast to the Type I-E system show primed adaptation in both strands (Li et al., 2014b;
200 Richter et al., 2014). In Type I-F systems, the distribution of acquired spacers exhibits a
201 gradient centered at the targeted protospacer (Fig. 3). A clear gradient is not observed for
202 Type I-B, yet less acquisition in distant regions compared to the primed protospacer was
203 observed.

204 Two major hypotheses have been proposed for the observed strand selection. The first
205 hypothesis suggests that degradation products, generated by the interference machinery
206 Cascade and Cas3, are preferentially used as spacer donors. The degradation fragments are
207 produced in a defined orientation dictated by the helicase directionality of Cas3 primarily
208 on one strand (Sinkunas et al., 2013; Swarts et al., 2012). This model, however, is difficult
209 to reconcile with the fact that a protospacer with seed or PAM mutations, is less efficiently
210 targeted by the interference machinery than a fully cognate protospacer, yet primes
211 acquisition more efficiently. Another hypothesis suggests that DNA “sliding” by the
212 interference proteins takes place following initial binding to a protospacer (Datsenko et al.,
213 2012). This hypothesis assumes that sliding continues until an appropriate spacer adjacent
214 to a cognate PAM is reached. Spacer acquisition in the region next to the targeted
215 protospacer should be highest and gradually decrease as a function of distance from that
216 spacer. Acquisition centered on the priming protospacer was indeed observed in the Type

217 I-F system, supporting the sliding hypothesis (Richter et al., 2014). However, both
218 predictions of sliding were not fulfilled in a high-throughput analysis of spacers acquired
219 from a plasmid in a Type I-E system (Savitskaya et al., 2013).

220 Recent biophysical studies of Type I-E started to shed light on the mechanism of primed
221 adaptation, and in particular, how the interference machinery recruits the acquisition
222 proteins. Early *in vitro* studies showed that Cascade weakly binds to protospacers
223 containing mutated PAM or seed sequence (Semenova et al., 2011; Westra et al., 2013b),
224 suggesting that cells would select against such sequences and/or Cas3 recruitment would
225 fail. Recent single-molecule experiments demonstrated that a non-canonical Cascade
226 binding mode persists at mutated protospacers and may be involved during primed
227 adaptation (Blosser et al., 2015). Even protospacers with a mutated PAM can elicit highly
228 stable Cascade binding (Szczelkun et al., 2014). These studies, together with the
229 identification of a specific intermolecular Cascade-Cas3 interaction (Hochstrasser et al.,
230 2014) indicate that recognition of a consensus PAM by Cascade is required for functional
231 recruitment of Cas3 to promote an interference response (Hochstrasser et al., 2014), leaving
232 open the question how mutated PAMs and/or protospacers elicit priming in a
233 Cascade/Cas3-dependent process.

234 Real-time single-molecule fluorescence imaging was used to directly visualize Cascade
235 and Cas3 binding to protospacers with either a consensus or mutated PAM that elicits
236 interference or priming *in vivo*, respectively (Redding et al., 2015). The results confirmed
237 that only consensus PAM binding promotes Cas3 recruitment. Strikingly, the addition of
238 Cas1-Cas2 enabled Cascade to specifically recruit Cas3 to protospacers with a mutated
239 PAM. Moreover, with the mutated PAM Cas3 could translocate in both directions, unlike
240 the unidirectional translocation from the protospacer with consensus PAM. Based on these
241 data, it was proposed that Cas3 may travel in complex with Cas1-Cas2, forming a larger
242 spacer acquisition complex. The 3'→5' translocation behavior along both strands could
243 explain the strand bias of newly acquired spacers relative to the priming protospacer
244 (Datsenko et al., 2012; Li et al., 2014b; Richter et al., 2014). Supporting experiments with
245 a Type I-F system revealed a direct interaction between Cas1 and Cas3 (Richter et al.,
246 2012). Early proteomics experiments also revealed an interaction between Cas1 and

247 multiple subunits of Cascade (Babu et al., 2011), providing a molecular basis by which
248 Cas1-Cas2 might assist in Cas3 recruitment. Recent experiments have similarly provided
249 evidence for direct interactions between Cas9 and Cas1 in the Type II-A system (Heler et
250 al., 2015), highlighting how interference and acquisition machineries are linked in diverse
251 CRISPR-Cas systems.

252 *Regulation of adaptation*

253 Spacer adaptation can be a lethal process if self-spacers are acquired. Regulators of
254 CRISPR-Cas interference that act mostly through transcription were identified in several
255 systems. For example, the *E. coli* Type I-E system is regulated by the cAMP receptor
256 protein (CRP) (Yang et al., 2014), histone-like nucleoid-structuring protein (H-NS)
257 (Pougach et al., 2010; Pul et al., 2010), high-temperature protein G (Yosef et al., 2011) and
258 LeuO (Westra et al., 2010). However, few studies have demonstrated regulation at the level
259 of adaptation activity of the systems.

260 In *E. coli*, it was shown that both naïve and primed adaptation occur in the absence of the
261 negative regulator H-NS (Swarts et al., 2012). H-NS represses the promoter of the operon
262 that comprises the genes encoding Cascade, *cas1* and *cas2*, as well as transcription of the
263 CRISPR array. H-NS decreases adaptation by its repressive effect on the promoter of the
264 *cas* gene operon. A robust positive regulator of the adaptation system was recently
265 identified in the *Sulfolobus islandicus* Type I-A system (Liu et al., 2015). Csa3a is encoded
266 adjacent to the *cas* operon and was shown to bind two promoters regulating the adaptation
267 genes. Its overexpression resulted in robust naïve adaptation with low specificity for spacer
268 donors flanking cognate PAMs (67-74%). This concurs with low levels observed for naïve
269 adaptation in the *E. coli* Type I-E system (Savitskaya et al., 2013; Yosef et al., 2012).

270 In the *Pectobacterium atrosepticum* Type I-F system, the CRP protein was shown to
271 positively regulate the expression of the entire *cas* operon by binding to a consensus motif
272 located upstream of the *cas1* gene (Patterson et al., 2015). Activation was cAMP-dependent
273 and required the AMP cyclase gene, *cyaA*. Glucose and gene products such as GalM, which
274 elevates the concentration of the AMP cyclase, reduced the CRP-CyaA-dependent *cas*
275 operon transcription. Deletion of the CRP and CyaA activators decreased primed

276 adaptation, whereas deletion of the *galM* gene increased primed adaptation. Interestingly,
277 the CRP regulator increases both adaptation and interference in *P. atrosepticum*. It further
278 increases *cas* gene transcription in the *Thermus thermophilus* Type I-E and Type III-A
279 systems, yet represses interference in the *E. coli* Type I-E system. These opposing
280 regulatory roles may reflect the unique niches that different bacteria occupy. The reverse
281 roles played by this regulator, reveal that regulation of CRISPR-Cas systems, even within
282 a same subtype, is complex and not universal to all systems. Despite the above studies, it
283 is still elusive whether adaptation is driven by an invasive genetic element or by a general
284 stress-response-like phenomenon.

285 **Adaptation in Type II CRISPR-Cas systems**

286 The first documented adaptation was shown in *S. thermophilus* (Barrangou et al., 2007).
287 New spacer sequences derived from infecting lytic phage integrated into the CRISPR array.
288 Resulting bacteriophage insensitive mutants (BIMs) were immune to repeated infections.
289 Using strains with a defective *csn2* gene demonstrated that this gene is required for efficient
290 acquisition of new spacer sequences.

291 Long-term co-culture experiments of *S. thermophilus* with phage 2972 indicated that the
292 uptake of chromosomal spacer sequences resulting in autoimmunity is lethal for the cell as
293 selection against these sequences occurs (Paez-Espino et al., 2013; Wei et al., 2015a).
294 Spacer contents of Type II-A CRISPR arrays are shown to be highly diverse (Horvath et
295 al., 2008; Lopez-Sanchez et al., 2012), yet recent experiments show that a bias towards
296 certain spacer sequences of the phage genome may reflect the effectiveness of an explicit
297 spacer (Paez-Espino et al., 2013), albeit that in long-term experiments a selection against
298 ineffective or un-functional spacer sequences occurs.

299 Using similar experimental setups as described above for Type I, Terns and co-workers set
300 out to identify *cis*-acting elements involved in spacer acquisition in Type II systems.
301 Similar to the findings of the *E. coli* Type I-E system, the leader and a single repeat are
302 sufficient for efficient spacer uptake (Wei et al., 2015a). Furthermore, 10 bp of the leader
303 sequence at the leader-repeat junction are essential for adaptation and an identified ATTGA
304 motif directly at the leader-repeat junction is highly conserved among the CRISPR-Cas

305 systems of different streptococci (Wei et al., 2015a). Similar sequence dependencies were
306 observed for the leader proximal nucleotides of the repeat; introduction of single or double
307 nucleotide exchanges affected adaptation, whereas repeat alterations at the leader distal
308 part had no effect. The leader proximal repeat nucleotides are essential for spacer
309 acquisition but have no impact on crRNA biogenesis or interference (Wei et al., 2015a).

310 Remarkably, Type II also requires Cas9 and tracrRNA as another essential elements during
311 adaptation (Heler et al., 2015; Wei et al., 2015b). Bacteria lacking Cas9 were unable to
312 acquire new spacers, whereas Cas9 availability restored spacer uptake during phage
313 infection (Heler et al., 2015; Wei et al., 2015b). Experiments using either Cas9 of *S.*
314 *pyogenes* or *S. thermophilus* demonstrated a functional interchangeability of these proteins.
315 The observed PAMs for newly acquired spacers perfectly matched the PAM specificity of
316 the respective Cas9, leading to the hypothesis that Cas9 defines the PAM during adaptation.
317 To confirm this, catalytically inactive Cas9 and variants with mutated PAM recognition
318 residues were tested. Remarkably, catalytically inactive Cas9 still enabled robust spacer
319 acquisition with the correct PAM, whereas new spacers without defined PAM were
320 acquired when the PAM-interacting residues were mutated (Heler et al., 2015; Wei et al.,
321 2015b). Earlier studies in Type I demonstrated that proteins involved in adaptation form
322 large multi-subunit complexes (Nunez et al., 2014; Plagens et al., 2012). Similarly, possible
323 interactions between all four proteins required for adaptation (Cas9, Cas1, Cas2 and Csn2)
324 were indicated for Type II-A (Heler et al., 2015).

325 In most cases, during a brief period of phage attack, the CRISPR-Cas system must acquire
326 a spacer from an invading phage, generate mature crRNAs, assemble the interference
327 complex and target nucleic acids from the phage in order to prevent lysis. Using defective
328 phages to infect *S. thermophilus* Hynes and colleagues demonstrated that this treatment is
329 similar to classical vaccination (Hynes et al., 2014). Phages damaged by UV-light result in
330 defective phages that are less potent in killing the bacteria. The frequency of spacer uptake
331 was higher upon infections with a defective phage compared to infections using wild-type
332 phage. The defective phage thus appears to “buy” time and allow the CRISPR-Cas system
333 to adapt and mount an immune response.

334 **Adaptation in Type III CRISPR-Cas systems and other pathways**

335 Given the high diversity of CRISPR-Cas subtypes, it is not surprising that pathways other
336 than the described naïve and primed adaptation exist. Studies of the CRISPR-Cas systems
337 of *Sulfolobales* identified a unique spacer acquisition pattern. The different species of
338 *Sulfolobus* that are under investigation in the Garrett laboratory contain multiple systems
339 of Type I and Type III. Garrett and colleagues were able to observe spacer acquisition
340 after challenging *S. solfataricus* with a mixture of phages isolated from Yellowstone
341 National Park. Interestingly, the sequenced spacers matched to open reading frames of a
342 conjugative plasmid indicative that this spacer uptake was only observed during co-
343 infection with the conjugative plasmid (Erdmann and Garrett, 2012). Analysis of the
344 integration site revealed that most of the spacers were integrated proximal to the leader as
345 was reported previously for Type I (Yosef et al., 2012). A few exceptions were found for
346 one CRISPR locus in which new spacers were inserted at different repeats of the array with
347 the majority being integrated after the fourth repeat. Similar results were obtained when *S.*
348 *islandicus* was infected with a phage mixture and spacers were only acquired from one of
349 the two phages (Erdmann et al., 2014). In the latter case, adaptation was directly associated
350 to a Type I-A system. Many thermophilic organisms tend to have more than one CRISPR
351 array and it is often difficult to directly assign the arrays to a specific CRISPR-Cas system.
352 It is possible that acquisition events observed in *S. solfataricus* were actually adaptation
353 events associated to the activity of the Type I-A system (Erdmann and Garrett, 2012;
354 Erdmann et al., 2014). In agreement, it was shown that the Type III-B system of *S.*
355 *solfataricus* exploited the Cas6a enzyme of the Type I-A system to process the Type III-B
356 crRNAs (Deng et al., 2013). The identification of PAMs for the newly acquired spacers in
357 *S. solfataricus* (Erdmann and Garrett, 2012) can be seen as further evidence, since Type III
358 systems do not utilize PAMs during target interference. Furthermore, Type III-B systems
359 often lack an adaptation module (Erdmann et al., 2013; Shah et al., 2013). Therefore, it is
360 tempting to speculate about a cross-talk among these types with respect to adaptation.
361 Interestingly, spacers were not acquired from the wild-type virus that stimulated spacer
362 acquisition from other foreign DNA sources. These observations highlight yet another
363 possible adaptation mechanism that should be further elucidated.

364 **Self versus non-self discrimination during adaptation**

365 Spacers represent potential targets for the interference machinery, as they bear perfect
366 complementarity to the crRNAs they encode. In Type III, the extended base-pair
367 complementarity of crRNAs with the repeats in the array prevents autoimmunity
368 (Marraffini and Sontheimer, 2010). In Type I and Type II, targeting during interference
369 occurs through specific recognition of the PAM adjacent the protospacer (Sashital et al.,
370 2011; Semenova et al., 2011; Westra et al., 2013a). The absence of PAMs in spacer-
371 flanking sequences in the CRISPR array prevents self-recognition. Consistent with early
372 studies proposing that PAM specificity occurs upon spacer selection (Mojica et al., 2009),
373 naïve adaptation assays have revealed that the acquisition machinery also has an intrinsic
374 PAM specificity (Yosef et al., 2012; Yosef et al., 2013). Independent recognition of the
375 PAM during both adaptation and interference may increase the ability to prevent a lethal
376 autoimmune response. This redundancy may further explain the enhanced specificity of
377 spacer acquisition with consensus PAM during primed over naïve adaptation (Savitskaya
378 et al., 2013). PAM specificity during adaptation and interference of Type I are overlapping
379 but non-identical (Fineran et al., 2014; Yosef et al., 2012).

380 Mutations in the PAM or seed sequence of a protospacer (Deveau et al., 2008; Fineran et
381 al., 2014; Semenova et al., 2011), substantially reduce the binding affinity of Cascade
382 (Semenova et al., 2011; Westra et al., 2013a) and perturb the recruitment and/or cleavage
383 activity of the Cas3 nuclease (Hochstrasser et al., 2014; Rutkauskas et al., 2015) in Type
384 I-E systems leading to evasion of interference. A high-throughput study examining
385 sequence determinants of interference and priming demonstrated that up to 13 mutations
386 within the protospacer and at least 22 mutated PAMs still elicit a priming response in Type
387 I-E (Fineran et al., 2014). Similarly, up to 19 mutated PAMs elicited priming for Type I-
388 B, as well as the 4 consensus PAMs that function for interference (Li et al., 2014a),
389 highlighting the plasticity with which the interference machinery can adapt to escape
390 phage. In the latter study, priming was abrogated when the mutated PAM matched the 3'
391 end of the spacer flanking repeat sequence, explaining how self-priming is specifically
392 avoided.

393 Naïve adaptation experiments demonstrated that Cas1 and Cas2 of Type I-E prefer spacers
394 from plasmids rather than the chromosome, despite the large excess of chromosomal DNA
395 (Yosef et al., 2012). The chromosomal DNA content was ~25-50 times greater than the
396 plasmid DNA content. Yet, chromosome-derived spacers represented only ~2-22% of the
397 total spacers acquired, depending on Cas1 and Cas2 expression levels. This represents a
398 100-1000 fold preference in spacer acquisition from plasmid over the chromosome. The
399 observed ratio seems rather due to inherent preference for foreign DNA in the adaptation
400 process, than selective pressure against chromosomal spacer acquisition. In contrast, such
401 preference was not observed for naïve adaptation in the Type II-A system of *S.*
402 *thermophilus*, indicating that protection from self-immunity may operate via a different
403 pathway (Wei et al., 2015b).

404 A recent model proposes that two main mechanisms account for this preference (Levy et
405 al., 2015). One mechanism was deciphered after discovering that the recombination/repair
406 complex RecBCD facilitates adaptation. RecBCD is known to interact with an octamer
407 sequence called Crossover Hotspot Instigator (Chi) (Smith, 2012). It was shown that
408 acquisition is significantly higher from protospacers located immediately upstream of a
409 Chi site, suggesting that Cas1 and Cas2 may depend on RecBCD for spacer acquisition,
410 and that Chi sites may attenuate their activity (Levy et al., 2015). The observation that the
411 *E. coli* chromosome contains a ~15-fold overrepresentation of Chi sites compared to
412 plasmids suggests a mechanism for specific avoidance of self-DNA. In fact, spacer
413 acquisition was specifically reduced from a plasmid containing additional Chi sites (Levy
414 et al., 2015) (Fig. 4). The second mechanism explaining foreign DNA preference was
415 revealed when spacer acquisition hotspots were found upstream of replication stalling sites
416 called Ter sites (Levy et al., 2015). During bidirectional DNA replication, Ter sites stall
417 the faster-moving replication fork until the slower replication fork completes replication,
418 allowing for chromosome decatenation (Neylon et al., 2005). DNA nicks and double-strand
419 breaks, which also stall the replication fork, exhibited additional hotspots. These findings
420 suggested that spacer acquisition is highest from DNA regions undergoing frequent
421 replication stalls. The high copy number of plasmids consequently means a greater
422 occurrence of termination replication events, compared to chromosomal DNA replication,

423 which terminates only once in each growth cycle. Thus, the acquisition machinery should
424 exhibit a natural preference for any high-copy DNA (Fig. 4).

425 **Structural insights into adaptation**

426 The nuclease/integrase function of Cas1 was predicted in 2006 (Makarova et al., 2006),
427 and the adjacency of the *cas1* and *cas2* genes in most *cas* operons led to the hypothesis of
428 functional cooperation between both proteins in spacer acquisition (Makarova et al., 2006;
429 Makarova et al., 2011). Numerous studies have attempted to make inroads into the
430 mechanism of adaptation through structural studies of Cas1 (~30 kDa) and Cas2 (~10 kDa).

431 Cas1 proteins from six different bacteria and one phage have been crystallized (Babu et al.,
432 2011; Kim et al., 2013; Wiedenheft et al., 2009); 4 unpublished). Cas1 adopts a novel fold
433 that can be divided into an N-terminal domain comprising primarily β -strands and a C-
434 terminal α -helical domain (Fig. 5A). Interactions between the N-terminal domains from
435 adjacent protomers promote stable Cas1 dimerization, and the C-terminal domain contains
436 three highly conserved residues (E141, H208, D221; *E. coli* numbering) coordinating a
437 divalent metal ion and forming the putative active site (Wiedenheft et al., 2009). Studies
438 of Cas1 from *P. aeruginosa*, *E. coli* and *A. fulgidus* demonstrated that mutating any of these
439 residues largely eliminated the observed nuclease activity. However, the structures failed
440 to provide significant insights into substrate specificity, and nuclease activity was observed
441 against a range of different substrates, including ssRNA, ssDNA, dsDNA, branched DNA,
442 and plasmid DNA structures (Babu et al., 2011; Kim et al., 2013; Wiedenheft et al., 2009).

443 Studies of Cas2 similarly show various enzyme activities. An early study detected nuclease
444 activity on ssRNA substrates but not DNA for six different Cas2 homologs (Beloglazova
445 et al., 2008), whereas subsequent studies observed either no nuclease activity (Samai et al.,
446 2010), or degradation of dsDNA (Ka et al., 2014; Nam et al., 2012). Regardless of whether
447 these differences are artifacts or result from the evolutionary distance separating the tested
448 homologs, Cas2 crystal structures presented in these studies, reveal a highly conserved
449 three-dimensional architecture. Cas2 is a small, single-domain protein that exhibits the
450 ferredoxin-like fold also found in Cas5 and Cas6 proteins (Li, 2015), and like Cas1, Cas2
451 forms a stable homodimer (Fig. 5A).

452 A breakthrough in the structural understanding of spacer acquisition was the finding that
453 Cas1 and Cas2 assemble into a larger complex, and that complex formation facilitates *in*
454 *vitro* spacer integration, CRISPR DNA binding, and is critical for adaptation *in vivo* (Nunez
455 et al., 2014; Nunez et al., 2015b). The crystal structure of Cas1-Cas2 from *E. coli* (Nunez
456 et al., 2014) reveals a heterohexameric, crab-like architecture with pseudo-two-fold
457 symmetry, in which a central Cas2 dimer interacts on two opposite faces with separate
458 Cas1 dimers (Fig. 5A). The Cas1-Cas2 interface is stabilized by a combination of
459 electrostatic and hydrophobic interactions. Impairment of this interface perturbs complex
460 formation *in vitro*, as well as spacer acquisition *in vivo*. While purified Cas1-Cas2 showed
461 non-specific DNA binding, perhaps reflecting the flexibility of spacer donor sequences,
462 overexpressed Cas1-Cas2 in cell lysate specifically bound DNA containing a CRISPR
463 array and leader sequence. This suggests that yet unidentified accessory factors may
464 facilitate loading of Cas1-Cas2 onto the CRISPR array for efficient integration.
465 Furthermore, specific CRISPR DNA binding by Cas1 was dependent on the presence of
466 Cas2, suggesting that the primary role of Cas2 may be conformational and involves
467 restructuring of Cas1. In agreement with this hypothesis, spacer acquisition *in vivo* was
468 completely unaffected by Cas2 active site mutations, however abolished by Cas1 active
469 site mutations.

470 Two recently reported crystal structures of the *E. coli* Cas1-Cas2 complex bound to spacer
471 donor DNA substrates, shedding light on the mechanisms of foreign DNA capture, PAM
472 recognition and CRISPR integration (Nunez et al., 2015a; Wang et al., 2015). The Cas1-
473 Cas2 complex binds a splayed, dual-fork DNA substrate in which 23-bp of dsDNA are
474 flanked by 3' single-stranded overhangs that are threaded into two, symmetry-related Cas1
475 active sites (Fig. 5B). Tyrosine residues from the same Cas1 monomers (Y22) bracket the
476 double-stranded region *via* stacking interactions, explaining how Cas1-Cas2 acts as a
477 caliper to accurately measure the length of new spacers. These residues may act like a
478 wedge to generate double-strand/single-strand junctions. Wang *et al.* succeeded in
479 crystallizing Cas1-Cas2 with a spacer donor containing the PAM, revealing the molecular
480 details of PAM selection during naïve adaptation (Fig. 5D) (Wang et al., 2015). Cas1
481 specifically recognizes the PAM-complementary 5'-CTT-3' sequence within the 3' single-
482 stranded overhang region. This helps to position the phosphodiester bond following the C

483 nucleotide within the Cas1 active site, that spacer donor precursors can be trimmed down
484 to the correct length (Fig. 5B). Finally, using data from alternative crystal forms, Nunez *et*
485 *al.* proposed an intriguing structural model that explains how Cas1-Cas2 may position
486 spacer donor and acceptor CRISPR DNA to promote the integration reaction (Nunez et al.,
487 2015a).

488 **Conclusions and future directions**

489 Numerous studies have been published on the interference activity of CRISPR-Cas
490 immune systems and only a few dozen studies have been published on the adaptation step.
491 It remains the least understood pathway in CRISPR-Cas immunity. Below, we list several
492 key issues that in our opinion must be resolved for a deeper understanding of the adaptation
493 process.

494 *Spacer biogenesis*

495 How foreign DNA is processed into the spacer donor that is further integrated into the
496 CRISPR array is a question that requires thorough examination. For example, it is yet
497 unclear how spacer donors are excised and loaded onto the Cas1-Cas2 complex. Other
498 questions involve the precise roles of RecBCD and Cas3 during naïve and primed
499 adaptation in Type I-E systems.

500 *Leader recognition*

501 New spacers are mostly integrated at the leader-repeat boundary of CRISPR arrays (Yosef
502 et al., 2012). However, it was shown *in vitro* that spacers can be inserted at sites even
503 outside of the CRISPR array (Nunez et al., 2015b). It is possible that the recognition of the
504 leader-proximal repeat sequence requires additional proteins other than Cas1 and Cas2.

505 *Mechanism of primed adaptation*

506 The priming mechanism is still elusive. A gradient of spacers centered near the primed
507 protospacer was observed in one experimental set-up (Richter et al., 2014). Thus, sliding
508 from the primed site is a reasonable mechanism for primed adaptation. The components of
509 this sliding complex could be Cascade, Cas3, Cas1 and Cas2, or a complex of Cas1, Cas2

510 and Cas3. In the latter case, the main role of Cascade may be to mediate interactions
511 between the Cas1-Cas2 complex and Cas3. The interplay between these proteins is a major
512 question to be elucidated.

513 *More studies required for Type III adaptation*

514 Knowledge about spacer acquisition in Type III systems is sparse. The typical lack of Cas1
515 and Cas2 in Type III-B and the co-occurrence of Type III systems together with another
516 Type I or Type II system highlight the potential of cross-talks among these systems. It is
517 noteworthy that the vast amount of these systems exists in bacteria and archaea that are not
518 easy to manipulate or for which the access to phages is limited. Heterologous expression
519 systems are more experimentally tractable and could help to overcome these drawbacks.

520 **Acknowledgements**

521 We thank Moran Goren and Konstantin Severinov for constructive comments and Michael
522 Namestnikov for graphic help. U.Q. is supported in part by the European Research Council
523 Starting Grant 336079, the Israel Science Foundation grant 268/14, and the Israeli Ministry
524 of Health grant 9988-3. E.C. is supported in part by the Alexander von Humboldt
525 Foundation (Professorship), the German Federal Ministry for Education and Research, the
526 Helmholtz Association, the Max Planck Society, the Swedish Research Council and Umeå
527 University. H.R. is a recipient of the Helmholtz Post-doctoral programme.

528 **Author Contribution**

529 S.H.S, H.R, E.C. and U.Q wrote the manuscript.

530 **References**

- 531 Arslan, Z., Hermanns, V., Wurm, R., Wagner, R., and Pul, U. (2014). Detection and
532 characterization of spacer integration intermediates in type I-E CRISPR-Cas system. *Nucleic Acids*
533 *Res.*
- 534 Babu, M., Beloglazova, N., Flick, R., Graham, C., Skarina, T., Nocek, B., Gagarinova, A., Pogoutse,
535 O., Brown, G., Binkowski, A., *et al.* (2011). A dual function of the CRISPR-Cas system in bacterial
536 antiviral immunity and DNA repair. *Mol Microbiol* **79**, 484-502.
- 537 Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D.A.,
538 and Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes.
539 *Science* **315**, 1709-1712.
- 540 Beloglazova, N., Brown, G., Zimmerman, M.D., Proudfoot, M., Makarova, K.S., Kudritska, M.,
541 Kochinyan, S., Wang, S., Chruszcz, M., Minor, W., *et al.* (2008). A novel family of sequence-
542 specific endoribonucleases associated with the clustered regularly interspaced short palindromic
543 repeats. *J Biol Chem* **283**, 20361-20371.
- 544 Blosser, T.R., Loeff, L., Westra, E.R., Vlot, M., Kunne, T., Sobota, M., Dekker, C., Brouns, S.J., and
545 Joo, C. (2015). Two distinct DNA binding modes guide dual roles of a CRISPR-Cas protein
546 complex. *Mol Cell* **58**, 60-70.
- 547 Brouns, S.J., Jore, M.M., Lundgren, M., Westra, E.R., Slijkhuis, R.J., Snijders, A.P., Dickman, M.J.,
548 Makarova, K.S., Koonin, E.V., and van der Oost, J. (2008). Small CRISPR RNAs guide antiviral
549 defense in prokaryotes. *Science* **321**, 960-964.
- 550 Datsenko, K.A., Pougach, K., Tikhonov, A., Wanner, B.L., Severinov, K., and Semenova, E. (2012).
551 Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity
552 system. *Nat Commun* **3**, 945.
- 553 Deng, L., Garrett, R.A., Shah, S.A., Peng, X., and She, Q. (2013). A novel interference mechanism
554 by a type IIIB CRISPR-Cmr module in *Sulfolobus*. *Mol Microbiol* **87**, 1088-1099.
- 555 Deveau, H., Barrangou, R., Garneau, J.E., Labonte, J., Fremaux, C., Boyaval, P., Romero, D.A.,
556 Horvath, P., and Moineau, S. (2008). Phage response to CRISPR-encoded resistance in
557 *Streptococcus thermophilus*. *J Bacteriol* **190**, 1390-1400.
- 558 Diez-Villasenor, C., Guzman, N.M., Almendros, C., Garcia-Martinez, J., and Mojica, F.J. (2013).
559 CRISPR-spacer integration reporter plasmids reveal distinct genuine acquisition specificities
560 among CRISPR-Cas I-E variants of *Escherichia coli*. *RNA Biol* **10**, 792-802.
- 561 Erdmann, S., and Garrett, R.A. (2012). Selective and hyperactive uptake of foreign DNA by
562 adaptive immune systems of an archaeon via two distinct mechanisms. *Mol Microbiol* **85**, 1044-
563 1056.
- 564 Erdmann, S., Le Moine Bauer, S., and Garrett, R.A. (2014). Inter-viral conflicts that exploit host
565 CRISPR immune systems of *Sulfolobus*. *Mol Microbiol* **91**, 900-917.
- 566 Erdmann, S., Shah, S.A., and Garrett, R.A. (2013). SMV1 virus-induced CRISPR spacer acquisition
567 from the conjugative plasmid pMGB1 in *Sulfolobus solfataricus* P2. *Biochem Soc Trans* **41**, 1449-
568 1458.
- 569 Fineran, P.C., Gerritzen, M.J., Suarez-Diez, M., Kunne, T., Boekhorst, J., van Hijum, S.A., Staals,
570 R.H., and Brouns, S.J. (2014). Degenerate target sites mediate rapid primed CRISPR adaptation.
571 *Proc Natl Acad Sci U S A* **111**, E1629-1638.
- 572 Garneau, J.E., Dupuis, M.E., Villion, M., Romero, D.A., Barrangou, R., Boyaval, P., Fremaux, C.,
573 Horvath, P., Magadan, A.H., and Moineau, S. (2010). The CRISPR/Cas bacterial immune system
574 cleaves bacteriophage and plasmid DNA. *Nature* **468**, 67-71.

575 Hale, C.R., Zhao, P., Olson, S., Duff, M.O., Graveley, B.R., Wells, L., Terns, R.M., and Terns, M.P.
576 (2009). RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. *Cell* *139*, 945-956.
577 Heler, R., Samai, P., Modell, J.W., Weiner, C., Goldberg, G.W., Bikard, D., and Marraffini, L.A.
578 (2015). Cas9 specifies functional viral targets during CRISPR-Cas adaptation. *Nature* *519*, 199-
579 202.

580 Hochstrasser, M.L., Taylor, D.W., Bhat, P., Guegler, C.K., Sternberg, S.H., Nogales, E., and
581 Doudna, J.A. (2014). CasA mediates Cas3-catalyzed target degradation during CRISPR RNA-
582 guided interference. *Proceedings of the National Academy of Sciences of the United States of*
583 *America* *111*, 6618-6623.

584 Horvath, P., Romero, D.A., Coute-Monvoisin, A.C., Richards, M., Deveau, H., Moineau, S.,
585 Boyaval, P., Fremaux, C., and Barrangou, R. (2008). Diversity, activity, and evolution of CRISPR
586 loci in *Streptococcus thermophilus*. *J Bacteriol* *190*, 1401-1412.

587 Hynes, A.P., Villion, M., and Moineau, S. (2014). Adaptation in bacterial CRISPR-Cas immunity
588 can be driven by defective phages. *Nat Commun* *5*, 4399.

589 Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A
590 Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science*.
591 Ka, D., Kim, D., Baek, G., and Bae, E. (2014). Structural and functional characterization of
592 *Streptococcus pyogenes* Cas2 protein under different pH conditions. *Biochem Biophys Res*
593 *Commun* *451*, 152-157.

594 Kim, Y.K., Kim, Y.G., and Oh, B.H. (2013). Crystal structure and nucleic acid-binding activity of the
595 CRISPR-associated protein Csx1 of *Pyrococcus furiosus*. *Proteins* *81*, 261-270.

596 Levy, A., Goren, M.G., Yosef, I., Auster, O., Manor, M., Amitai, G., Edgar, R., Qimron, U., and
597 Sorek, R. (2015). CRISPR adaptation biases explain preference for acquisition of foreign DNA.
598 *Nature* *520*, 505-510.

599 Li, H. (2015). Structural Principles of CRISPR RNA Processing. *Structure* *23*, 13-20.

600 Li, M., Wang, R., and Xiang, H. (2014a). *Haloarcula hispanica* CRISPR authenticates PAM of a
601 target sequence to prime discriminative adaptation. *Nucleic Acids Res* *42*, 7226-7235.

602 Li, M., Wang, R., Zhao, D., and Xiang, H. (2014b). Adaptation of the *Haloarcula hispanica* CRISPR-
603 Cas system to a purified virus strictly requires a priming process. *Nucleic Acids Res* *42*, 2483-
604 2492.

605 Liu, T., Li, Y., Wang, X., Ye, Q., Li, H., Liang, Y., She, Q., and Peng, N. (2015). Transcriptional
606 regulator-mediated activation of adaptation genes triggers CRISPR de novo spacer acquisition.
607 *Nucleic acids research* *43*, 1044-1055.

608 Lopez-Sanchez, M.J., Sauvage, E., Da Cunha, V., Clermont, D., Ratsima Hariniaina, E., Gonzalez-
609 Zorn, B., Poyart, C., Rosinski-Chupin, I., and Glaser, P. (2012). The highly dynamic CRISPR1
610 system of *Streptococcus agalactiae* controls the diversity of its mobilome. *Mol Microbiol* *85*,
611 1057-1071.

612 Makarova, K.S., Grishin, N.V., Shabalina, S.A., Wolf, Y.I., and Koonin, E.V. (2006). A putative RNA-
613 interference-based immune system in prokaryotes: computational analysis of the predicted
614 enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms
615 of action. *Biol Direct* *1*, 7.

616 Makarova, K.S., Wolf, Y.I., Alkhnbashi, O.S., Costa, F., Shah, S.A., Saunders, S.J., Barrangou, R.,
617 Brouns, S.J., Charpentier, E., Haft, D.H., *et al.* (2015). An updated evolutionary classification of
618 CRISPR-Cas systems. *Nature reviews. Microbiology*.

619 Marraffini, L.A. (2015). CRISPR-Cas immunity in prokaryotes. *Nature* *526*, 55-61.

620 Marraffini, L.A., and Sontheimer, E.J. (2008). CRISPR interference limits horizontal gene transfer
621 in staphylococci by targeting DNA. *Science* *322*, 1843-1845.

622 Marraffini, L.A., and Sontheimer, E.J. (2010). Self versus non-self discrimination during CRISPR
623 RNA-directed immunity. *Nature* 463, 568-571.

624 Mojica, F.J., Diez-Villasenor, C., Garcia-Martinez, J., and Almendros, C. (2009). Short motif
625 sequences determine the targets of the prokaryotic CRISPR defence system. *Microbiology* 155,
626 733-740.

627 Mojica, F.J., Diez-Villasenor, C., Garcia-Martinez, J., and Soria, E. (2005). Intervening sequences
628 of regularly spaced prokaryotic repeats derive from foreign genetic elements. *J Mol Evol* 60,
629 174-182.

630 Nam, K.H., Huang, Q., and Ke, A. (2012). Nucleic acid binding surface and dimer interface
631 revealed by CRISPR-associated CasB protein structures. *FEBS Lett* 586, 3956-3961.

632 Neylon, C., Kralicek, A.V., Hill, T.M., and Dixon, N.E. (2005). Replication termination in
633 *Escherichia coli*: structure and antihelicase activity of the Tus-Ter complex. *Microbiol Mol Biol*
634 *Rev* 69, 501-526.

635 Nunez, J.K., Harrington, L.B., Kranzusch, P.J., Engelman, A.N., and Doudna, J.A. (2015a). Foreign
636 DNA capture during CRISPR-Cas adaptive immunity. *Nature*.

637 Nunez, J.K., Kranzusch, P.J., Noeske, J., Wright, A.V., Davies, C.W., and Doudna, J.A. (2014). Cas1-
638 Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity.
639 *Nature structural & molecular biology* 21, 528-534.

640 Nunez, J.K., Lee, A.S., Engelman, A., and Doudna, J.A. (2015b). Integrase-mediated spacer
641 acquisition during CRISPR-Cas adaptive immunity. *Nature* 519, 193-198.

642 Paez-Espino, D., Morovic, W., Sun, C.L., Thomas, B.C., Ueda, K., Stahl, B., Barrangou, R., and
643 Banfield, J.F. (2013). Strong bias in the bacterial CRISPR elements that confer immunity to
644 phage. *Nat Commun* 4, 1430.

645 Paez-Espino, D., Sharon, I., Morovic, W., Stahl, B., Thomas, B.C., Barrangou, R., and Banfield, J.F.
646 (2015). CRISPR immunity drives rapid phage genome evolution in *Streptococcus thermophilus*.
647 *MBio* 6.

648 Patterson, A.G., Chang, J.T., Taylor, C., and Fineran, P.C. (2015). Regulation of the Type I-F
649 CRISPR-Cas system by CRP-cAMP and GalM controls spacer acquisition and interference. *Nucleic*
650 *Acids Res*.

651 Plagens, A., Tjaden, B., Hagemann, A., Randau, L., and Hensel, R. (2012). Characterization of the
652 CRISPR/Cas subtype I-A system of the hyperthermophilic crenarchaeon *Thermoproteus tenax*. *J*
653 *Bacteriol* 194, 2491-2500.

654 Pougach, K., Semenova, E., Bogdanova, E., Datsenko, K.A., Djordjevic, M., Wanner, B.L., and
655 Severinov, K. (2010). Transcription, processing and function of CRISPR cassettes in *Escherichia*
656 *coli*. *Mol Microbiol* 77, 1367-1379.

657 Pourcel, C., Salvignol, G., and Vergnaud, G. (2005). CRISPR elements in *Yersinia pestis* acquire
658 new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for
659 evolutionary studies. *Microbiology* 151, 653-663.

660 Pul, U., Wurm, R., Arslan, Z., Geissen, R., Hofmann, N., and Wagner, R. (2010). Identification and
661 characterization of *E. coli* CRISPR-cas promoters and their silencing by H-NS. *Mol Microbiol* 75,
662 1495-1512.

663 Redding, S., Sternberg, S.H., Marshall, M., Gibb, B., Bhat, P., Guegler, C.K., Wiedenheft, B.,
664 Doudna, J.A., and Greene, E.C. (2015). Surveillance and Processing of Foreign DNA by the
665 *Escherichia coli* CRISPR-Cas System. *Cell* 163, 854-865.

666 Richter, C., Dy, R.L., McKenzie, R.E., Watson, B.N., Taylor, C., Chang, J.T., McNeil, M.B., Staals,
667 R.H., and Fineran, P.C. (2014). Priming in the Type I-F CRISPR-Cas system triggers strand-
668 independent spacer acquisition, bi-directionally from the primed protospacer. *Nucleic Acids Res*
669 42, 8516-8526.

670 Richter, C., Gristwood, T., Clulow, J.S., and Fineran, P.C. (2012). In vivo protein interactions and
671 complex formation in the *Pectobacterium atrosepticum* subtype I-F CRISPR/Cas System. *PLoS*
672 *One* 7, e49549.

673 Rutkauskas, M., Sinkunas, T., Songailiene, I., Tikhomirova, M.S., Siksny, V., and Seidel, R. (2015).
674 Directional R-Loop Formation by the CRISPR-Cas Surveillance Complex Cascade Provides Efficient
675 Off-Target Site Rejection. *Cell reports*.

676 Samai, P., Smith, P., and Shuman, S. (2010). Structure of a CRISPR-associated protein Cas2 from
677 *Desulfovibrio vulgaris*. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 66, 1552-1556.

678 Sapranaukas, R., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., and Siksny, V. (2011).
679 The *Streptococcus thermophilus* CRISPR/Cas system provides immunity in *Escherichia coli*.
680 *Nucleic Acids Res*.

681 Sashital, D.G., Jinek, M., and Doudna, J.A. (2011). An RNA-induced conformational change
682 required for CRISPR RNA cleavage by the endoribonuclease Cse3. *Nature structural & molecular*
683 *biology* 18, 680-687.

684 Savitskaya, E., Semenova, E., Dedkov, V., Metlitskaya, A., and Severinov, K. (2013). High-
685 throughput analysis of type I-E CRISPR/Cas spacer acquisition in *E. coli*. *RNA Biol* 10.

686 Semenova, E., Jore, M.M., Datsenko, K.A., Semenova, A., Westra, E.R., Wanner, B., van der Oost,
687 J., Brouns, S.J., and Severinov, K. (2011). Interference by clustered regularly interspaced short
688 palindromic repeat (CRISPR) RNA is governed by a seed sequence. *Proc Natl Acad Sci U S A* 108,
689 10098-10103.

690 Shah, S.A., Erdmann, S., Mojica, F.J., and Garrett, R.A. (2013). Protospacer recognition motifs:
691 mixed identities and functional diversity. *RNA biology* 10, 891-899.

692 Shmakov, S., Savitskaya, E., Semenova, E., Logacheva, M.D., Datsenko, K.A., and Severinov, K.
693 (2014). Pervasive generation of oppositely oriented spacers during CRISPR adaptation. *Nucleic*
694 *Acids Res* 42, 5907-5916.

695 Sinkunas, T., Gasiunas, G., Waghmare, S.P., Dickman, M.J., Barrangou, R., Horvath, P., and
696 Siksny, V. (2013). In vitro reconstitution of Cascade-mediated CRISPR immunity in
697 *Streptococcus thermophilus*. *EMBO J* 32, 385-394.

698 Smith, G.R. (2012). How RecBCD enzyme and Chi promote DNA break repair and recombination:
699 a molecular biologist's view. *Microbiol Mol Biol Rev* 76, 217-228.

700 Sun, C.L., Thomas, B.C., Barrangou, R., and Banfield, J.F. (2015). Metagenomic reconstructions of
701 bacterial CRISPR loci constrain population histories. *Isme j*.

702 Swarts, D.C., Mosterd, C., van Passel, M.W.J., and Brouns, S.J.J. (2012). CRISPR Interference
703 Directs Strand Specific Spacer Acquisition. *PLoS One* 7, e35888.

704 Szczelkun, M.D., Tikhomirova, M.S., Sinkunas, T., Gasiunas, G., Karvelis, T., Pschera, P., Siksny,
705 V., and Seidel, R. (2014). Direct observation of R-loop formation by single RNA-guided Cas9 and
706 Cascade effector complexes. *Proc Natl Acad Sci U S A* 111, 9798-9803.

707 Wang, J., Li, J., Zhao, H., Sheng, G., Wang, M., Yin, M., and Wang, Y. (2015). Structural and
708 Mechanistic Basis of PAM-Dependent Spacer Acquisition in CRISPR-Cas Systems. *Cell* 163, 840-
709 853.

710 Wei, Y., Chesne, M.T., Terns, R.M., and Terns, M.P. (2015a). Sequences spanning the leader-
711 repeat junction mediate CRISPR adaptation to phage in *Streptococcus thermophilus*. *Nucleic*
712 *Acids Res* 43, 1749-1758.

713 Wei, Y., Terns, R.M., and Terns, M.P. (2015b). Cas9 function and host genome sampling in Type
714 II-A CRISPR-Cas adaptation. *Genes Dev* 29, 356-361.

715 Westra, E.R., Pul, U., Heidrich, N., Jore, M.M., Lundgren, M., Stratmann, T., Wurm, R., Raine, A.,
716 Mescher, M., Van Heereveld, L., *et al.* (2010). H-NS-mediated repression of CRISPR-based

717 immunity in *Escherichia coli* K12 can be relieved by the transcription activator LeuO. *Mol*
718 *Microbiol* *77*, 1380-1393.

719 Westra, E.R., Semenova, E., Datsenko, K.A., Jackson, R.N., Wiedenheft, B., Severinov, K., and
720 Brouns, S.J. (2013a). Type I-E CRISPR-cas systems discriminate target from non-target DNA
721 through base pairing-independent PAM recognition. *PLoS genetics* *9*, e1003742.

722 Westra, E.R., Staals, R.H., Gort, G., Hogg, S., Neumann, S., de la Cruz, F., Fineran, P.C., and
723 Brouns, S.J. (2013b). CRISPR-Cas systems preferentially target the leading regions of MOB
724 conjugative plasmids. *RNA Biol* *10*.

725 Wiedenheft, B., Zhou, K., Jinek, M., Coyle, S.M., Ma, W., and Doudna, J.A. (2009). Structural
726 basis for DNase activity of a conserved protein implicated in CRISPR-mediated genome defense.
727 *Structure* *17*, 904-912.

728 Yang, C.D., Chen, Y.H., Huang, H.Y., Huang, H.D., and Tseng, C.P. (2014). CRP represses the
729 CRISPR/Cas system in *Escherichia coli*: evidence that endogenous CRISPR spacers impede phage
730 P1 replication. *Molecular microbiology* *92*, 1072-1091.

731 Yosef, I., Goren, M.G., Kiro, R., Edgar, R., and Qimron, U. (2011). High-temperature protein G is
732 essential for activity of the *Escherichia coli* clustered regularly interspaced short palindromic
733 repeats (CRISPR)/Cas system. *Proc Natl Acad Sci U S A* *108*, 20136-20141.

734 Yosef, I., Goren, M.G., and Qimron, U. (2012). Proteins and DNA elements essential for the
735 CRISPR adaptation process in *Escherichia coli*. *Nucleic acids research* *40*, 5569-5576.

736 Yosef, I., and Qimron, U. (2015). Microbiology: How bacteria get spacers from invaders. *Nature*
737 *519*, 166-167.

738 Yosef, I., Shitrit, D., Goren, M., Burstein, D., Pupko, T., and Qimron, U. (2013). DNA motifs
739 determining the efficiency of adaptation into the *Escherichia coli* CRISPR array. *Proc Natl Acad*
740 *Sci U S A* *110*, 14396-14401.

Table 1. Model organisms discussed in this review.

CRISPR-Cas class	CRISPR-Cas type	organism	naïve / primed	reference
1	I-A	<i>Sulfolobus solfataricus</i> , <i>Sulfolobus islandicus</i>	naïve	(Erdmann and Garrett, 2012; Erdmann et al., 2014)
1	I-B	<i>Haloarcula hispanica</i>	primed	(Li et al., 2014a; Li et al., 2014b)
1	I-E	<i>Escherichia coli</i>	naïve + primed	(Datsenko et al., 2012; Diez-Villasenor et al., 2013; Fineran et al., 2014; Levy et al., 2015; Savitskaya et al., 2013; Shmakov et al., 2014; Swarts et al., 2012; Yosef et al., 2012; Yosef et al., 2013)
1	I-F	<i>Pectobacterium atrosepticum</i>	primed	(Richter et al., 2014)
2	II-A	<i>Streptococcus thermophilus</i>	naïve	(Barrangou et al., 2007; Deveau et al., 2008; Garneau et al., 2010; Wei et al., 2015a; Wei et al., 2015b)
2	II-A	<i>Streptococcus agalactiae</i>	naïve	(Lopez-Sanchez et al., 2012)
2	II-A	<i>Streptococcus pyogenes</i>		(Heler et al., 2015)
1	III-B / I-A ?	<i>S. solfataricus</i> , <i>S. islandicus</i>	naïve	(Erdmann and Garrett, 2012; Erdmann et al., 2014)

741 **Figure legends**

742 **Figure 1. Assays for detecting adaptation.** **A.** Bacteria with plasmid (green) driven
743 expression of Cas1 and Cas2 are grown for 1-3 days. PCR amplification of the CRISPR
744 array using genomic DNA as template followed by gel electrophoresis analysis reveals
745 both parental and expanded arrays. **B.** Same as in A, but using a spacer-specific primer to
746 allow only amplification of expanded arrays. A band on the gel is only observed when a
747 specific spacer was integrated. **C.** A plasmid-based CRISPR array leads to an antibiotic
748 resistance only upon spacer insertion and repeat duplication. **D.** Donor spacer, acceptor
749 plasmid, and Cas1 and Cas2 are mixed in a test tube. Intermediates of adaptation are
750 observed by gel electrophoresis analysis and further investigated by high-throughput DNA
751 sequencing. **E.** Bacteria harboring a plasmid are grown for 7-14 days. Adaptation is
752 recorded by plasmid curing. Antibiotic sensitive bacteria are then selected for spacer
753 acquisition analysis. **F.** Infection of bacteria by a phage results in low naïve acquisition, as
754 detected by PCR analysis (top). Acquisition primed by an existing spacer that targets the
755 invading DNA results in higher adaptation frequency (bottom).

756 **Figure 2. Model for spacer integration into the CRISPR array.** Donor DNA (green,
757 PAM in red) is inserted into a CRISPR array in a multi-step process. The processing events
758 that generate the mature donor DNA are unknown. Cas1 and Cas2 catalyze a nucleophilic
759 attack of the 3'-OH in an orientation dictated by the last nucleotide of the PAM. The
760 opposite 3'-OH end likely initiates another nucleophilic attack on the opposite strand of
761 the array followed by gap filling.

762 **Figure 3. Primed adaptation in Type I-E and I-F.** Adaptation is significantly enhanced
763 by the presence of Cascade, Cas3 and a 'priming' spacer matching the target DNA. Arrows
764 represent newly acquired spacers. In Type I-E, a gradient of spacers was not detected, yet
765 significantly preferred acquisition from one strand was observed. In Type I-F, a gradient
766 of spacers peaking near the priming protospacer was observed on both strands.

767

768 **Figure 4. A model for self and non-self discrimination in Type I-E. A.** In a RecBCD-
769 dependent mechanism Chi sites reduce the amount of sequences available for spacer donor
770 selection. **B.** Major hotspots for adaptation are replication-stall sites, such as replication
771 termination (lightning symbol). High-copy elements have more replication-stall sites than
772 the chromosome, leading to more frequent acquisition of spacers from these elements.

773 **Figure 5. Structure of the Type I-E acquisition complex. A.** Crystal structure of *E. coli*
774 Cas1-Cas2 complex (PDB 4P6I) (Nunez et al., 2014). A Cas2 dimer (light and dark green)
775 is sandwiched by two Cas1 dimers (light blue and grey), forming a ~150 kDa
776 heterohexameric complex. **B.** Crystal structure of the *E. coli* Cas1-Cas2 complex bound to
777 PAM-containing DNA (PDB 5DQZ) (Wang et al., 2015), colored as in A. The DNA
778 contains 23 base-pairs (bp) of dsDNA flanked by ssDNA overhangs. The inset (right)
779 shows how the PAM-complementary 5'-CTT-3' sequence is specifically recognized,
780 positioning the scissile phosphate in the active site.